Q-omics provides the consensus-scored TCF19 profile across patient tissues and cancer cell-line models. TCF19 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TCF19 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, TCF19 protein abundance shows 20,828 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, KIRC, and LUAD as cancer lineages where TCF19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCF19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCF19 survival associations across molecular data types. TCF19 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCF19 RNA expression–survival associations across cancer types. High TCF19 expression shows unfavorable associations in ACC, KIRP, MESO, KICH, LIHC and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TCF19 RNA expression.
This table summarizes TCF19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TCF19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCF19 shows higher tumor expression in KIRC, HNSC, COAD, BLCA, LIHC and LUAD. The KIRC box plot shows higher TCF19 RNA expression in tumor versus normal tissue (log2 FC = +1.522, t-test p < 0.001).
This table shows molecular features associated with TCF19 in patient tissues and cancer cell lines. In patient samples, TCF19 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TCF19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Myeloma.
